FDA approves 1st non-antipsychotic medication for agitation in Alzheimer's disease
ABC News - Breaking News, Latest News and Videos • • business
Key Points:
- The FDA has approved Auvelity, an extended-release tablet, for treating agitation in adults with Alzheimer's dementia, marking the first non-antipsychotic medication approved for this condition.
- Unlike antipsychotics, which carry serious risks such as stroke, sedation, and increased mortality in older adults, Auvelity may offer a safer alternative with a better tolerability profile.
- Auvelity, initially approved in 2022 for major depressive disorder, showed effectiveness in reducing agitation symptoms and delaying relapse in Alzheimer's patients through clinical trials, though it carries warnings for potential suicidal thoughts, seizures, and increased blood pressure.
- Agitation affects 50-60% of Alzheimer's patients and is linked to faster cognitive decline, higher mortality, earlier nursing home placement, and increased caregiver burden, highlighting the need for improved treatment options.
- Experts emphasize that beyond medication, lifestyle factors like exercise, diet, and managing health risks can help improve brain health and Alzheimer's outcomes, offering hope for patients and families.
